Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBP-A13 in advanced solid tumors
NCT06298058Phase 1Recruiting
- Sponsor
- Shanghai Institute of Biological Products
- Start
- May 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SIBP-A13 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), breast cancer and 1 more, sponsored by Shanghai Institute of Biological Products. Primary endpoints: Adverse Events, Serious Adverse Events and 5 more. Started May 2024; status: recruiting.
02
Drugs
SIBP-A13
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)breast cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06298058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06298058.